quinazolines has been researched along with enzastaurin in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stummer, W | 1 |
| Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; Daniele, G; Gelardi, T; Lahn, M; Pepe, S; Tortora, G | 1 |
| Chhatwani, L; Colevas, AD; Decker, R; Fisher, GA; Krupitskaya, Y; Latz, JE; Padda, SK; San Pedro-Salcedo, M; Wakelee, HA | 1 |
| Bernstein, ED; Clément-Duchêne, C; Dudek, AZ; Jahan, T; Krupitskaya, Y; Latz, JE; Natale, RB; Osarogiagbon, R; Sanborn, RE; Shi, P; Wakelee, HA | 1 |
| Cartron, PF; Cheray, M; Nadaradjane, A; Pacaud, R; Vallette, FM | 1 |
2 trial(s) available for quinazolines and enzastaurin
| Article | Year |
|---|---|
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Quinazolines | 2012 |
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome | 2012 |
3 other study(ies) available for quinazolines and enzastaurin
| Article | Year |
|---|---|
Perspectives in central nervous system malignancies.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Combined Modality Therapy; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Glioma; Humans; Indoles; Protein Kinase C; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; TOR Serine-Threonine Kinases | 2006 |
Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Culture Media, Conditioned; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Humans; Indoles; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
Histone H3 phosphorylation in GBM: a new rational to guide the use of kinase inhibitors in anti-GBM therapy.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Glioblastoma; Histones; Humans; Indoles; Male; Middle Aged; Organophosphates; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrazoles; Pyrimidines; Quinazolines; Temozolomide | 2015 |